Fogorvosi szemle, 2013 (106. évfolyam, 1-4. szám)

2013-06-01 / 2. szám

59

FOGORVOSI SZEMLE ■ 106. évf. 2. sz. 2013.

45. Gyurkovics M, Lohinai Z, Gyorfi A, Bodor C, Fazekas A, Nyarasdy I, és mtsai: Gingival venule diameter is regulated through the increased VEGF expression in experimental diabetes. Acta Physiologica Hungarica 2010; 97: 104-105.

46. Gyurkovics M, Lohinai Z, Gyorfi A, Bodor C, Szekely AD, Dinya E, és mtsai: Microvascular regulatory role and increased expression of vascular endothelial growth factor receptor type 2 in experimental gingivitis. J Periodontal Res 2013; 48: 194-202.

47. Suda O, Smith L. A, D'uscio LV, Peterson TE, Katusic Z S: In vivo expression of recombinant vascular endothelial growth factor in rabbit carotid artery increases production of superoxide anion. Arterioscler Thromb Vase Biol 2005; 25: 506-511.

48. Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson K L, és mtsai: Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sei USA 2002; 99: 7734-7739.

49. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'amore PA: Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003; 264: 275-288.

50. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, és mtsai: Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 1999; 79: 501-509.

51. Lohinai Z, Szabo C: Role of nitric oxide in physiology and pathophysiology of periodontal tissues. Med Sei Mónit 1998; 4: 1089-1095.

Gyurkovics M, Lohinai Z, Győrfi A, Székely DA,

Dinya E, Fazekas Á, Rosivall L

Investigation of the venodilatory effect of vascular endothelial growth factor (VEGF) in rat gingiva

VEGF induces proliferation of endothelial cells, stimulates angiogenesis, and increases vascular permeability in many organs. Nevertheless, we have only limited information about its role on gingival hemodynamics, especially in venules. Therefor the aim of this study was to assess the acute circulatory effects of VEGF on rat gingival venules by means of the following protocol.

Wister rats (n=63) were devided into five study groups after anesthesia; each animal received 10 pi of experimental solution dripped onto the lower interincisal gingiva. The groups included: 1) saline control (after the experiment, gingiva was excised for VEGF receptor 2 [VEGFR2] immunohistochemistry); 2) VEGF (0.1,1,10, or 50 pg/ml); 3) VEGF2 receptor antagonist 5-((7-benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methyl-phenol-hydrochloride (ZM323881 ; 20 pg/ml); 4) ZM323881 (20 pg/ml) followed by VEGF application (50 pg/ml after 15 minutes); and 5) VEGF (10 pg/ml), these rats were premedicated with nitric oxide (NO) synthase blocker (NG-nitro-L-arginine-methyl-ester [L-NAME]; 1 mg/ml in drinking water) for 1 week before the experiment. Changes in gingival superficial venule diameter were measured by vital microscopy prior to and 1,5, 15, 30, and 60 minutes after the administration of the experimental solutions.

According to our findings, VEGF dose-dependently increased the venular diameter compared to saline. ZM323881 alone did not cause any alteration. Premedication with ZM323881 or L-NAME decreased the dilatory effects of VEGF. Occassionally moderate VEGFR2 immunohistochemical labeling was observed in the wall components of the venules. Concluding our results we can say, that there is no remarkable VEGF production under physiologic circumstances in rat gingiva, but VEGF is able to increase gingival blood flow through the activation of VEGF2 receptors and consequent NO release.

Key words: VEGF; VEGFR; vasodilation; NO